- Home
- DOYU vs SLGL Comparison
DOYU vs SLGL Comparison
Compare DOYU & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | SLGL |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 159.7M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DOYU | SLGL |
|---|---|---|
| Price | $5.11 | $80.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 52.5K | 11.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $0.40 |
| 52 Week High | $9.93 | $97.97 |
Technical Indicators
Market Signals| Indicator | DOYU | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 55.73 |
| Support Level | $4.28 | $32.56 |
| Resistance Level | $7.11 | $97.97 |
| Average True Range (ATR) | 0.39 | 9.88 |
| MACD | 0.04 | -1.27 |
| Stochastic Oscillator | 57.81 | 47.55 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.